After Howson, it's clear that the drug "Fusha pitan" has been approved.

　　Medicine Network November 1st, October 30th, Zheng datianqing announced that its injection with Fusapitan metformin was approved, the commodity named Good Qi fasciator of the phosaphatinis is an NK1 receptor antagonist, an atriotintorine pre-phosphate drug that is quickly converted into aripitan in the body after injection and then selectively binds to the brain NK1 receptor through the blood-brain barrier, with little or no affinity for 5-HT3, dopamine and corticosteroid receptors It effectively inhibits nausea caused by cytotoxic chemotherapy agents and enhances the anti-spitting activity of the 5-HT3 receptor antagonist endothel and corticosteroid dexamethasone Fushapitan was approved by the FDA in 2008 for intravenous powder edphylaxis to prevent nausea and vomiting caused by chemotherapy drugs fusapitan is widely used in the clinic Since Fusapitan is metabolized by most non-liver tissues, no dose adjustment is required for patients with mild to moderate liver insufficiency (Child-Pugh grade 5 to 9) Patients with severe renal insufficiency (CrCl 30mL/min) and patients with advanced renal (ESRD) who need edhemolydial do not require dose adjustment Although oral aripartan is suitable for most patients, for some patients with vague awareness or disease-related nausea that can not tolerate oral administration, the choice of injection administration can provide greater flexibility and convenience, so injection with fasatin metformin also has a large market demand In June 2019, Phosapitan metformin was included in the List of First Recommendations to Encourage Imitation 2019/10/15, Haussen Injection with Fassapitan metformin? (product name: Tanon) was approved for listing by the FDA.